U.S. Office REITs Stock News

CNX Resources recently announced executive changes, with Everett Good set to become Chief Financial Officer and Alan Shepard moving into the roles of President, CEO, and board member effective January 1, 2026. This leadership transition comes alongside strong third-quarter results and increased production guidance, highlighting both continuity in financial leadership and operational momentum for the company. We'll examine how the upcoming management transition and operational performance...

Steel Dynamics recently declared a fourth quarter 2025 cash dividend of US$0.50 per common share, payable on or about January 9, 2026, and earlier announced the launch of low-carbon steel products, BIOEDGE™ and EDGE™, produced using electric arc furnace technology and renewable or emission-free energy certifications. The rollout of these steel offerings aims to help customers in sectors such as automotive, construction, and renewable energy achieve their sustainability goals, reflecting...

Wondering if Innodata’s stellar rally makes it a buy, or if it’s running too hot? Let’s take a close look at what’s really under the hood before talking price tags. The share price has soared 64.8% year-to-date and is up 52.2% over the last year, but it has cooled off lately with a -30.1% drop in the last month and -12.7% over the past week. Behind these recent swings, headlines have spotlighted Innodata’s growing foothold in AI data solutions, as partnerships with leading tech firms have...

Zillow Group (ZG) just posted its third-quarter earnings, revealing a swing to profitability and double-digit revenue growth compared to last year. The company also reaffirmed full-year guidance and shared a positive outlook for the upcoming quarter. See our latest analysis for Zillow Group. After a year marked by new features and steady innovation, Zillow Group’s financial momentum appears to be catching the market’s eye. The stock is now trading at $70.81, with a modest 2.79% share price...

Merit Medical Systems (MMSI) saw attention after unveiling positive 24-month results from the WAVE trial for its WRAPSODY Cell-Impermeable Endoprosthesis. The data, announced during a leading vascular conference, showed the device’s superior performance compared to standard treatment. See our latest analysis for Merit Medical Systems. After a tough year for total shareholders, news like the positive WAVE trial results is sparking fresh interest. Merit’s share price has climbed 4.6% over the...

Earlier this month, PPG Industries introduced a new ultrafiltration antifouling membrane for industrial water purification, designed to handle complex oily waste streams and other tough contaminants without intentionally-added PFAS. This launch highlights PPG's focus on sustainable innovation in water treatment technology, adding to its production capabilities and broad industrial applications. Let's explore how PPG's investment in next-generation water filtration could shape its growth and...

MDU Resources Group (MDU) has delivered a strong stretch of returns over the past year, gaining 20% in that time and building further momentum in recent months. Investors are now weighing what comes next for this diversified infrastructure company. See our latest analysis for MDU Resources Group. The past year has been a strong one for MDU Resources Group, with its latest share price pushing to $20.90 and recent momentum especially visible over the last month. The stock’s 1-year total...

NETSTREIT Corp. recently reported third quarter 2025 results, posting US$45.03 million in sales and a net income of US$618,000, a turnaround from a net loss in the prior year period. The Board of Directors declared a quarterly cash dividend increase, taking the annualized payout to US$0.86 per share, signaling confidence in the company's ongoing earnings recovery. We will now examine how the improved profitability and increased dividend inform NETSTREIT’s investment outlook and risk...

Insmed Incorporated recently reported a third quarter net loss of US$370.02 million but raised its 2025 global ARIKAYCE revenue guidance to between US$420 million and US$430 million, signifying higher growth expectations for the product. This updated revenue outlook comes despite an increase in net loss for both the quarter and year-to-date, highlighting expansion in ARIKAYCE demand even as overall losses continue to widen. We'll examine how the improved ARIKAYCE revenue forecast shapes...

Kite Realty Group Trust (KRG) just wrapped up an eventful stretch, rolling out third quarter earnings, issuing fresh net income guidance for 2025, increasing its fourth quarter dividend by 7%, and completing a significant share buyback. See our latest analysis for Kite Realty Group Trust. While Kite Realty Group Trust’s latest share buyback, updated guidance, and dividend boost have caught investors’ attention, the stock’s momentum has yet to shift meaningfully. The year-to-date share price...

Federal Agricultural Mortgage, fresh off announcing higher net income and earnings per share for the third quarter and year-to-date period, is also rewarding shareholders with affirmed dividends across its common and preferred stock classes. These actions highlight consistent financial momentum and a commitment to shareholder returns. See our latest analysis for Federal Agricultural Mortgage. After the encouraging earnings and dividend affirmations, Federal Agricultural Mortgage’s share price...

LiveWire Group, Inc. recently announced its third-quarter 2025 financial results, updated its full-year operating loss guidance to US$72 million–US$77 million, and showcased several new electric motorcycles and product initiatives at the EICMA International Motorshow in Milan. The company's expanded product lineup, including the European debut of the S4 Honcho and the unveiling of a new maxi-scooter developed with KYMCO, highlights a shift toward broader market accessibility and innovation...

Earlier this week, Johnson & Johnson announced it received U.S. FDA approvals for DARZALEX FASPRO® as a single-agent treatment for high-risk smoldering multiple myeloma and for CAPLYTA as an adjunctive therapy in major depressive disorder. The DARZALEX FASPRO® approval marks the first FDA-authorized therapy for early-stage HR-SMM, and expands Johnson & Johnson's offerings in oncology and psychiatric medicines based on robust Phase 3 trial data. We'll explore how these recent FDA approvals...

Arrowhead Pharmaceuticals is approaching a key FDA decision on November 18, 2025, for its RNAi therapy Plozasiran targeting familial chylomicronemia syndrome, following strong efficacy in Phase 3 trials with substantial reduction in triglycerides and pancreatitis risk. Additionally, Novartis has announced a global licensing agreement for development of ARO-SNCA, bringing Arrowhead significant upfront payments and milestone opportunities that strengthen its financial position before potential...

Vornado Realty Trust recently reported its third-quarter 2025 results, achieving a turnaround with net income of US$27.12 million compared to a net loss a year earlier, supported by revenue of US$453.7 million and key gains from property transactions including a master lease with New York University. Investor interest was further fueled by Vornado's strong leasing activity in Manhattan, acquisition and redevelopment plans for 623 Fifth Avenue, and expectations for increased Penn District...

Capital Southwest (CSWC) just posted earnings that topped expectations, completing a busy quarter that included new investments and a $350 million bond raise. The company also declared regular and supplemental dividends for shareholders. See our latest analysis for Capital Southwest. After a strong earnings beat and a successful $350 million bond raise, Capital Southwest’s momentum has started to gain traction. The share price recently saw a modest rebound, up nearly 2% over the past week to...

Janux Therapeutics (JANX) just released its third quarter and nine-month financial results, catching the eye of investors. The company trimmed its quarterly net loss compared to the previous year. However, its net loss for the year to date increased. See our latest analysis for Janux Therapeutics. Janux Therapeutics’ latest earnings update came amid a turbulent period for the stock, with a 1-day share price drop of 7.6%, and a 7-day slide of 7.8%. Even with recent volatility, its 30-day share...

In recent weeks, Carnival Corporation’s Holland America Line announced its 2027-2028 South America and Antarctica cruise season, offering immersive itineraries to landmark destinations like Machu Picchu and the Galapagos Islands with extended sailings aboard Zuiderdam and Oosterdam. This expansion into highly curated and remote cruise offerings highlights the company’s continued focus on unique guest experiences and on broadening appeal to adventure and nature-focused travelers. We’ll...

Brown & Brown, Inc. recently announced its third quarter 2025 results, reporting revenue of US$1.61 billion and net income of US$227 million, alongside an active acquisition outlook according to their CEO's commentary on seeking both domestic and international deals. While revenue increased compared to the prior year, net income saw a slight decline and the company paused share repurchases for this period, completing earlier buybacks totaling over 16.5 million shares. Given the CEO's ongoing...

Nexstar Media Group (NXST) shares edged up slightly today, catching the eye of investors after a mostly flat week and a modest month-long dip. With the company showing stable annual revenue and net income growth, some are revisiting their outlook. See our latest analysis for Nexstar Media Group. Nexstar’s share price has cooled a bit recently, but the bigger picture is hard to ignore. After a strong rally year to date and a 19.7% total shareholder return over the past year, momentum is still...

Dyne Therapeutics reported its third quarter and nine-month financial results for the period ended September 30, 2025, posting a net loss of US$108.04 million for the quarter and US$334.26 million for the nine months. The company is also set to present updates and engage with the investment community at several major healthcare investor conferences through the end of 2025. We'll explore how the widening net loss shapes Dyne Therapeutics' investment narrative amid ongoing engagement with the...

On November 6, 2025, Sunstone Hotel Investors, Inc.'s Board of Directors authorized cash dividends on both its common and preferred stock classes, with dividends payable on January 15, 2026, to stockholders of record as of December 31, 2025, and reaffirmed its 2025 earnings guidance. Sunstone Hotel Investors also reported quarterly financial results that exceeded consensus revenue and funds from operations estimates, pointing to continued operational momentum and the company's focus on...

Crinetics Pharmaceuticals recently announced the U.S. FDA approval and commercial launch of PALSONIFY (paltusotine) for treating adults with acromegaly, reporting early metrics of prescription uptake and field force coverage. This milestone marks Crinetics' transition to a commercial-stage company, supported by a strong cash position expected to fund operations into 2029 and ongoing advances in its clinical pipeline. With early signs of PALSONIFY’s market acceptance, we’ll explore how this...

Alexander & Baldwin, Inc. recently amended its US$450 million revolving credit facility, adding a new term loan facility of up to US$200 million, and raised its 2025 earnings guidance to a range of US$0.95 to US$1 per diluted share. These developments point to a focus on both financial flexibility and growth opportunities, particularly as the company actively searches for acquisitions in Hawaii’s competitive investment market. Let's examine how the creation of this new term loan facility...